Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles

Lee, Jung Ryeol; Choi, Young Sik; Jee, Byung Chul; Ku, Seung‐Yup; Suh, Chang Suk; Kim, Chul; Lee, Won Don; Kim, Seok Hyun

doi:10.1016/j.fertnstert.2007.01.013

Cited by 12 publications

(9 citation statements)

References 35 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the potential adverse effects of GnRH antagonist on oocyte or endometrium are still controversial. Several studies comparing the outcome of cryopreservedthawed ET for GnRH agonist and GnRH antagonist protocols demonstrated that GnRH antagonist has no direct negative effect on the quality of oocytes and embryos (25, 26). With regards the effect of GnRH antagonists versus agonists on endometrial development, the results are quite conflicting (27, 28).…”

Section: Discussionmentioning

confidence: 99%

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

et al. 2009

Self Cite

View full text Add to dashboard Cite

This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when leading follicle reached 14 mm in diameter until the day of hCG administration (Group A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and the number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in Group B compared to Group A (2.7±0.8 vs. 3.2±0.9 ampoules). There was no premature luteinization in the subjects. The proportion of mature oocytes (71.4% vs. 61.7%) and fertilization rate of mature (86.3±19.7% vs. 71.8±31.7%) was significantly higher in Group B. There were no significant differences in embryo quality and clinical pregnancy rates. Our results suggest that cessation of the GnRH antagonist on the day of hCG administration during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising IVF results.

show abstract

Section: Discussionmentioning

confidence: 99%

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Eldar-Geva et al reported that a lower IVF embryo transfer success using a GnRH-antagonist/GnRHagonist protocol does not appear to be related to an adverse effect on oocyte quality [16]. Lee et al have suggested that GnRH antagonists do not have a detrimental effect on oocyte quality or embryo development [17].…”

Section: Discussionmentioning

confidence: 99%

The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome

Yanaihara

Yorimitsu²,

Motoyama³

et al. 2008

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose While performing the mild ovarian stimulation protocol with a GnRH antagonist, the pregnancy rate was compared between the groups, which were divided by the degree that the luteinizing hormone (LH) level decreased. Materials and methods Patients aged 27 to 42years (36.1 ± 3.79) underwent 308 IVF cycles who opted for IVF via the mild ovarian stimulation protocol began clomiphene citrate on day 3 and recombinant FSH on day 5. A GnRH antagonist was administered when the dominant follicle reached 14mm. Serum LH was measured at the time of GnRH antagonist administration and at the time of hCG injection. The pregnancy rate and implantation rate were compared between 50 cycles in which the LH level dropped less than one-third and the control (LH level within 1/3). Result(s) The pregnancy rate for the group in which the LH level fell less than one third was 18%. Conversely, the pregnancy rate for the control group was 39%. The implantation rate was 18% for the less than one-third group and 26% for the control group. Both the pregnancy rate and the implantation rate for the group in which the LH level fell less than one-third were significantly lower than that of control (p < 0.02). Conslusion(s) When performing the mild ovarian stimulation protocol, serum LH should be followed. If the serum LH level is less than one-third at the time of hCG injection, both the pregnancy rate and implantation rate are significantly lower.

show abstract

“…Although the meta-analyses tend to indicate comparable ongoing pregnancies between agonists and antagonists, recent studies still stress for the agonist in young patients (36). Studies on transfer of frozen embryos reported similar outcome between the two groups, suggesting no different effects on oocyte and embryo developmental potential (16).…”

Section: Figure 1 Continuedmentioning

confidence: 99%

“…The GnRH antagonist in human ART was shown to be beneficial in reducing the amount of gonadotropin required, the risk of ovarian hyperstimulation syndrome (OHSS) and costs (4-6, 10, 11). However, the efficiency of GnRH antagonist in human ART remains controversial as some studies reported lower PRs after GnRH antagonist (4,7,12), whereas others reported comparable outcome between the two treatments (13)(14)(15)(16).…”

mentioning

confidence: 99%

Mitochondrial distribution and activity in human mature oocytes: gonadotropin-releasing hormone agonist versus antagonist for pituitary down-regulation

Dell’Aquila

Ambruosi

Santis

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles

Cited by 12 publications

References 35 publications

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome

Mitochondrial distribution and activity in human mature oocytes: gonadotropin-releasing hormone agonist versus antagonist for pituitary down-regulation

Contact Info

Product

Resources

About